Please use this identifier to cite or link to this item:
http://repository.kln.ac.lk/handle/123456789/23822
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mettananda, S. | |
dc.date.accessioned | 2021-11-02T06:58:59Z | |
dc.date.available | 2021-11-02T06:58:59Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Frontiers in Genome Editing.2021;3:752278. | en_US |
dc.identifier.issn | 2673-3439 (Electronic) | |
dc.identifier.uri | http://repository.kln.ac.lk/handle/123456789/23822 | |
dc.description | Not indexed in MEDLINE, In PUBMED | en_US |
dc.description.abstract | β-Thalassaemia is caused by over 300 mutations in and around the β-globin gene that lead to impaired synthesis of β-globin. The expression of α-globin continues normally, resulting in an excess of α-globin chains within red blood cells and their precursors. These unpaired α-globin chains form unstable α-hemichromes that trigger cascades of events to generate reactive oxygen species, leading to ineffective erythropoiesis and haemolysis in patients with β-thalassaemia. The clinical genetic data reported over several decades have demonstrated how the coinheritance of α-thalassaemia ameliorates the disease phenotype of β-thalassaemia. Thus, it is evident that down-regulation of the α-globin gene expression in patients with β-thalassaemia could ameliorate or even cure β-thalassaemia. Over the last few years, significant progress has been made in utilising this pathway to devise a cure for β-thalassaemia. Most research has been done to alter the epigenetic landscape of the α-globin locus or the well-characterised distant enhancers of α-globin. In vitro, pre-clinical studies on primary human erythroid cells have unveiled inhibition of histone lysine demethylation and histone deacetylation as potential targets to achieve selective downregulation of α-globin through epigenetic drug targeting. CRISPR based genome editing has been successfully used in vitro to mutate α-globin genes or enhancers of α-goblin to achieve clinically significant knockdowns of α-globin to the levels beneficial for patients with β-thalassaemia. This review summarises the current knowledge on the regulation of human α-globin genes and the clinical genetic data supporting the pathway of targeting α-globin as a treatment for β-thalassaemia. It also presents the progress of epigenetic drug and genome editing approaches currently in development to treat β-thalassaemia. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Frontiers Media S.A | en_US |
dc.subject | β-thalassaemia. | en_US |
dc.title | Genetic and epigenetic therapies for β-Thalassaemia by altering the expression of α-globin gene | en_US |
dc.type | Article | en_US |
Appears in Collections: | Journal/Magazine Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Mettanadana-Frontirers-2021.pdf | 897.72 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.